Mechanism of Action: UGT1A3 Inhibitors
✉ Email this page to a colleague
Drugs with Mechanism of Action: UGT1A3 Inhibitors
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-004 | Nov 29, 2023 | RX | Yes | Yes | 11,072,586 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-001 | Nov 29, 2023 | RX | Yes | No | 11,072,586 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-002 | Nov 29, 2023 | RX | Yes | No | 11,072,586 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Teva Pharms Inc | ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774-003 | Nov 29, 2023 | RX | Yes | No | 11,072,586 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Amneal | ELTROMBOPAG OLAMINE | eltrombopag olamine | TABLET;ORAL | 212884-003 | Jan 14, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
